

Medications:

- burosumab-twza (Crysvita)
- setmelanotide (Imcivree)
- vosoritide (Voxzogo)
- triheptanoin (Dojolvi)
- teprotumumab-trbw (Tepezza)
- avacopan (Tavenos)



Continuing Pharmacy Education for Pharmacist: Knowledge- Based Activity

Emerging Therapeutics Strategy Program - 2024
Medication Use Evaluation Presentations Part 3

Faculty: Kaiser Permanente Pharmacy Residents

Learning Objectives:

- Describe role of the Emerging Therapeutics Strategy Program (ETSP)
- Recall therapies currently reviewed within ETSP
- Recognize opportunities for practice performance improvement for ETSP emerging therapies

February 28, 2024

12:00pm-1:30 pm PT (3:00-4:30 ET)

Target Audience: Pharmacist

Kaiser Permanente National Pharmacy
Microsoft Teams webinar



Kaiser Foundation Health Plan of Southern California Department of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been accredited for pharmacists and assigned the Universal Activity Number 0393-0000-24-003-L01-P. It has been approved for 1.5 contact hours (0.15 CEU). For successful completion of this CPE activity, the participant must attend webinar and complete the electronic evaluation within 60 days of the program go-live date to receive credit and access the statement of credit. This CPE is internally funded by Kaiser Permanente and offered to Kaiser Permanente employees at no charge.